Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03553836 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
A Phase 3 study of Melanoma, sponsored by Merck Sharp & Dohme.
- Active
- Registry status
- Phase 3
- Development phase
- 976
- Enrollment target
- 20
- Study locations
NCT03553836 is a Phase 3 study of Melanoma that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 976 participants, above the 703-participant average among 266 other Melanoma trials with a reported enrollment target (39% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT03553836, a Phase 3 study of Melanoma, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 976 participants
- Enrollment target
- 20
- Study locations
Study Summary
This 2-part study will evaluate the safety and efficacy of pembrolizumab (MK-3475) compared to placebo in participants with surgically resected high-risk Stage II melanoma. Participants in Part 1 will receive either pembrolizumab or placebo in a double-blind design every 3 weeks (Q3W) for up to 17 cycles/\~1 year (each cycle = 21 days). Participants who complete the initial treatment of 17 cycles of pembrolizumab in Part 1 and experience disease recurrence may be eligible for re-challenge with pembrolizumab at the same dose and schedule of 200 mg Q3W (21-day cycles) for up to 35 cycles (up to \~2 years) in Part 2 in an open label design. Participants who complete the initial treatment of placebo and experience disease recurrence may be eligible to switch over to pembrolizumab 200 mg Q3W (21-day cycles) for up to 35 cycles (up to \~2 years) in Part 2 in an open label design. The primary hypothesis of this study is that pembrolizumab increases recurrence-free survival (RFS) compared to placebo. Per protocol, response/ progression or adverse events (AEs) during re-challenge/switch-over in Part 2 will not be counted towards the RFS outcome measure or safety outcome measures respectively.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- OTHER Placebo
Study Locations (20)
California
- UCSD Moores Cancer Center ( Site 0133) - La Jolla
- The Angeles Clinic and Research Institute ( Site 0029) - Los Angeles
- UCLA Hematology & Oncology ( Site 0130) - Los Angeles
- John Wayne Cancer Institute ( Site 0026) - Santa Monica
Illinois
- Northwestern Medical Group ( Site 0135) - Chicago
- The University of Chicago Medical Center ( Site 0007) - Chicago
- Advocate Medical Group-Park Ridge ( Site 0025) - Park Ridge
Massachusetts
- Massachusetts General Hospital ( Site 0126) - Boston
- Beth Israel Deaconess Medical Center ( Site 0141) - Boston
- Dana Farber Cancer Institute ( Site 0124) - Boston
Florida
- Mayo Clinic Florida ( Site 0024) - Jacksonville
- Moffitt McKinley Outpatient Center ( Site 0131) - Tampa
Georgia
- Winship Cancer Institute of Emory University ( Site 0046) - Atlanta
- Northside Hospital ( Site 0115) - Atlanta
Arizona
- University of Arizona Cancer Center ( Site 0121) - Tucson
Colorado
- University of Colorado Cancer Center ( Site 0027) - Aurora
Connecticut
- Yale University ( Site 0035) - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 976 participants |
| Start Date | 2018-09-12 |
| Est. Completion | 2033-10-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03553836
The ClinicalTrials.gov registry entry for NCT03553836 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 976 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 703-participant average among 266 other Melanoma trials with a reported enrollment target (39% higher). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03553836 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03553836 about?
NCT03553836 is a clinical study titled "Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)". This 2-part study will evaluate the safety and efficacy of pembrolizumab (MK-3475) compared to placebo in participants with surgically resected high-risk Stage II melanoma. Participants in Part 1 will receive either pembrolizumab or placebo in a double-blind design every 3 weeks (Q3W) for up to 17 c...
What is the current status of trial NCT03553836?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 976 participants. The study started on 2018-09-12. Estimated completion is 2033-10-12.
What conditions does trial NCT03553836 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT03553836?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Placebo (OTHER).
Who is sponsoring clinical trial NCT03553836?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03553836 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
RECRUITING · Phase 3
-
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
RECRUITING · Phase 3
-
Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy
ACTIVE NOT RECRUITING · Phase 3
-
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
ACTIVE NOT RECRUITING · Phase 3
-
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
ACTIVE NOT RECRUITING · Phase 3
-
Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.